Schrödinger and TB Alliance have entered into a three-year research collaboration to enhance the development of next-generation tuberculosis (TB) treatments by leveraging Schrödinger’s advanced computational platform for drug discovery.
Versant Ventures, through a $20m Series A financing, has launched Black Diamond Therapeutics, a biotechnology company focused on developing a new type of precision medicine for cancer.
e-therapeutics has entered into a research collaboration with Danish drug manufacturer Novo Nordisk to discover biological mechanisms and therapies to treat type-2 diabetes.
UK-based clinical-stage biopharmaceutical firm Mereo BioPharma Group and oncology-focused clinical stage biopharmaceutical business OncoMed Pharmaceuticals have agreed to merge.
Global biopharmaceutical company UCB is investing around £1bn in the UK for research and development, supporting the country’s life sciences sector.
Alphabet-owned DeepMind has claimed that research powered by artificial intelligence (AI) can help to predict the 3D structure of a protein on just its genetic sequence.
TRIGR Therapeutics has expanded bispecific immuno-oncology pipeline with exclusive global license of clinical stage, dual angiogenesis inhibitor from ABL Bio.
British drugmaker GlaxoSmithKline (GSK) has agreed to acquire US-based oncology-focused biopharmaceutical firm, Tesaro, for around £4bn ($5.1bn).
UK-based Redx Pharma said it expects to start first-in-man studies with RXC006 during 2020 as the first pre-clinical data of the drug candidate has suggested that the compound has great potential as a fibrosis treatment.
Aprea Therapeutics, a biopharmaceutical company engaged in the discovery and development of anticancer compounds that reactivate the tumor suppressor protein, p53, has closed a €50m Series C financing round.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.